Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,590 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ten new resin glycosides, ipoalbins I-X, from Ipomoea alba seeds.
Misuda N, Watanabe M, Nishikawa H, Yasuda S, Miyashita H, Yokomizo K, Yoshimitsu H, Tsuchihashi R, Okawa M, Kinjo J, Ono M. Misuda N, et al. Among authors: nishikawa h. J Nat Med. 2024 Dec 27. doi: 10.1007/s11418-024-01868-1. Online ahead of print. J Nat Med. 2024. PMID: 39729184
The tumor immune microenvironment and therapeutic efficacy of trastuzumab deruxtecan in gastric cancer.
Koganemaru S, Koyama S, Suto F, Koga M, Inaki K, Kuwahara Y, Arita T, Hirata T, Goto H, Wada N, Kobayashi M, Shibutani T, Okabayashi T, Nakamaru K, Kawazoe A, Togashi Y, Nishikawa H, Shitara K. Koganemaru S, et al. Among authors: nishikawa h. Cancer Res Commun. 2024 Dec 16. doi: 10.1158/2767-9764.CRC-24-0302. Online ahead of print. Cancer Res Commun. 2024. PMID: 39679910 Free article.
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.
Tsuge A, Watanabe S, Kawazoe A, Togashi Y, Itahashi K, Masuda M, Sai A, Takei S, Muraoka H, Ohkubo S, Sugiyama D, Yan Y, Fukuoka S, Doi T, Shitara K, Koyama S, Nishikawa H. Tsuge A, et al. Among authors: nishikawa h. Cancer Immunol Res. 2024 Nov 27. doi: 10.1158/2326-6066.CIR-24-0713. Online ahead of print. Cancer Immunol Res. 2024. PMID: 39602577
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; RELPEC Group and HCC 48 Group. Hiraoka A, et al. Among authors: nishikawa h. Hepatol Res. 2024 Nov 11. doi: 10.1111/hepr.14136. Online ahead of print. Hepatol Res. 2024. PMID: 39526824
1,590 results